Tag:

Hepatitis C

Latest Headlines

Latest Headlines

Armed with Indian approval, Gilead forges ahead with Sovaldi and its licensed copies

SINGAPORE-- Undeterred by its loss of a new patent bid for its Sovaldi (sofosbuvir) hepatitis C drug in India, Gilead Sciences put together package deals with 8 of the country's generics makers to add an experimental drug to a deal for low-cost copies in 91 poor countries around the world. Meanwhile, Gilead said Sovaldi won marketing approval this month in India and it's off and running in that country.

Gilead discounts hep C meds in Germany, offers new-and-improved generics deal in India

Gilead Sciences reportedly inked its first hepatitis C discount deals in Germany, and it's announcing a new offer to bring a Sovaldi follow-up to India even before it's approved in the U.S.

Another one bites the dust: Merck cans hep C fighter Victrelis as new meds take flight

Merck will stop selling Victrelis in the U.S. by the end of this year. The company cites "advances in treatment practices"--namely, the new all-oral drug cocktails offered by Gilead and AbbVie--and the shrinking demand they've caused.

Gilead, AbbVie rack up new payer deals, but hep C obstacles loom across the Atlantic

The hepatitis C market is breaking new ground all over the place. As payers put the squeeze on Gilead Sciences and AbbVie for discounts in the U.S., England's National Health Service is delaying a broad rollout of Gilead's blockbuster Sovaldi till July, citing the drug's high cost--an unprecedented move on a treatment already blessed by the country's cost-effectiveness watchdogs.

AbbVie wins quick approval for its hep C treatment in Europe

AbbVie has won European Commission approval for its oral hepatitis C cocktail, offering some positive news after some disappointments for the U.S. drugmaker in recent months. It also sets the stage for the drugmaker to take its marketing battle with Gilead Sciences to another continent.

Gilead blazes ahead in hep C pricing battle with two new PBM deals

Gilead Sciences is gaining ground in its hep C pricing battle with AbbVie. One week after the drugmaker joined forces with Anthem to make Harvoni the primary option for the PBM's 30 million patients, Gilead inked similar deals with Humana and Harvard Pilgrim, edging out its competitor and raising the stakes in the companies' ongoing war.  

Thanks to hep C pricing war, Gilead, AbbVie both score spots on Prime's coverage list

Better late than never? Try better late than early for Prime Therapeutics, which has scored deals on both sets of hepatitis C drugs. As  Bloomberg  reports, Gilead Sciences and AbbVie each offered prices low enough to justify putting Harvoni and Viekira Pak on its preferred formulary.

Gilead Sciences adds fuel to fire in hep C pricing battle with Anthem deal

Gilead is joining forces with Anthem, the biggest provider of health coverage to U.S. businesses, to make Harvoni the primary option for patients, setting the stage for a hep C showdown.

Express Scripts' Miller lays out manifesto to fight sky-high drug prices

It's no secret that Express Scripts Chief Medical Officer Steve Miller is hankering for some changes in the pharma business. But what many may not know, he told PharmExec, is that he's got a four-point solution to fix what he sees as the industry's biggest problems.

Hello, hep C pricing war: Gilead hits back at AbbVie with exclusive CVS deal

Gilead's got a message for you, AbbVie: It's on. Just a couple of weeks after the Illinois drugmaker struck an exclusive hep C pact with PBM Express Scripts, Gilead has come back with a deal of its own.